Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
571
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Sarit Assoulinea McGill University – Jewish General Hospital, Montreal, CanadaCorrespondence[email protected]
View further author information
,
Laura C. Michaelisb Medical College of Wisconsin, Milwaukee, WI, USAView further author information
,
Megan Othusc SWOG Statistics and Data Management Center, Seattle, WA, USAView further author information
,
Annette E. Hayd Queen’s University, Kingston, CanadaView further author information
,
Roland B. Waltere Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Meagan A. Jacobyf Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Mark A. Schroederf Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Geoffrey L. Uyf Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Lisa Y. Lawg Kaiser Permanente NCAL, Roseville, CA, USAORCID Iconhttps://orcid.org/0000-0001-7343-8212View further author information
ORCID Icon,
Faisal Cheemah Kaiser Permanente, Santa Clara, CA, USAView further author information
,
Kendra L. Sweeti Moffitt Cancer Center, Tampa, FL, USAView further author information
,
Adam S. Aschj University of Oklahoma HSC, Oklahoma City, OK, USAView further author information
,
Jijun (Jane) Liuk Illinois CancerCare/Heartland NCORP, Peoria, IL, USAView further author information
,
Anna B. Moseleyb Medical College of Wisconsin, Milwaukee, WI, USAORCID Iconhttps://orcid.org/0000-0002-7514-7360View further author information
ORCID Icon,
Tracy Maherl SWOG Data Operations Center/Cancer Research and Biostatistics, Seattle, WA, USAView further author information
,
Laura L. Kingsburyl SWOG Data Operations Center/Cancer Research and Biostatistics, Seattle, WA, USAView further author information
,
Min Fange Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Jerald Radiche Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Richard F. Littlem Cancer Therapy and Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, USAView further author information
&
Harry P. Erban Duke University Medical Center, Duke Cancer Institute, Durham, NC, USAView further author information
 show all
Pages 473-477 | Received 13 Jul 2022, Accepted 03 Nov 2022, Published online: 14 Dec 2022

References

  • Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood. 2007;110(11):817–817.
  • Serroukh Y, Hebert J, Busque L, et al. Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Rev. 2022;100991.
  • Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125(9):1470–1481.
  • Beyar-Katz O, Gill S. Novel approaches to acute myeloid leukemia immunotherapy. Clin Cancer Res. 2018;24(22):5502–5515.
  • Vadakekolathu J, Minden MD, Hood T, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020;12(546):eaaz0463.
  • Sallman DA, McLemore AF, Aldrich AL, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136(24):2812–2823.
  • Daver N, Boddu P, Garcia-Manero G, et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018;32(5):1094–1105.
  • Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–1288.
  • Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13(2):169–178.
  • Daver N, Garcia-Manero G, Basu S, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9(3):370–383.
  • Chien KS, Kim K, Nogueras-Gonzalez GM, et al. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021;195(3):378–387.
  • Walter RB, Michaelis LC, Othus M, et al. Intergroup LEAP trial (S1612): a randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol. 2018;93(2):E49–E52.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood. 2017;129(4):424–447.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
  • Zeidan AM, Boss I, Beach CL, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 2022;6(7):2207–2218.
  • Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27(5):997–999.
  • Abbas HA, Alaniz Z, Mackay S, et al. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv. 2021;5(22):4569–4574.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.